Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth (Status and Outlook) 2023-2029

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth (Status and Outlook) 2023-2029

Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.

LPI (LP Information)' newest research report, the “Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Industry Forecast” looks at past sales and reviews total world Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics sales for 2023 through 2029. With Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics industry.

This Insight Report provides a comprehensive analysis of the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics.

The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size is projected to grow from US$ 3428.8 million in 2022 to US$ 4589.5 million in 2029; it is expected to grow at a CAGR of 4.3% from 2023 to 2029.

United States market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics players cover AbbVie, Allergan, Nordmark Arzneimittel, Digestive Care, Janssen Pharmaceuticals, Cilian, Anthera Pharmaceuticals and AzurRx Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)

Segmentation by application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma

Please note: The report will take approximately 2 business days to prepare and deliver.